CNBX Pharmaceuticals
OTCMKTS:CNBXCNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. The company is a subsidiary of Cannabics Inc.
GB Sciences
OTCMKTS:GBLXGB Sciences, Inc., a phytomedical research and biopharmaceutical drug development company, engages in the research and development of plant-based medicines. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.
Medican Enterprises
OTCMKTS:MDCNMedican Enterprises, Inc., a bio-pharmaceutical company, focuses on pursuing business opportunities in the medical and recreational marijuana sector. The company intends to invest in business of growing, marketing, research and development, training, distribution, and retail sale of medical and recreational marijuana in the United States and Canada. Medican Enterprises, Inc. was founded in 1988 and is headquartered in Las Vegas, Nevada.
3SBio
OTCMKTS:TRSBF3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer in combination with chemotherapy; Interferon, a human interferon a2a for injection; and Inleusin, for the treatment of renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer and tuberculosis. It also offers YISAIPU, the receptor-antibody fusion tumor necrosis factor inhibitor; Mendi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium; and Xenopax, a recombinant humanized anti-cd25 monoclonal antibody injection for prevention of acute rejection after renal transplantation. In addition, the company provides TPO-105 Pediatric ITP; SSS12 Cinacalcet hydrochloride; SSS13 Sevelamer carbonate; 301S TNFR-Fc protein; AP506 Apremilast; SSS32 Tofacitinib; and MN709 Minoxidil Foam. Further, the company provides trading, project management and consultation, technology, sports, financial, investment advisory, and agricultural services. It has collaboration agreements with companies, such as Toray Industries Inc, and Toray. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.